New drug for CMV in trials. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

New drug for CMV in trials. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Treat Review. 1995 Jan;(no 16):3. Unique Identifier : AIDSLINE AIDS/95700311

Abstract: Two new trials are studying treatment of CMV retinitis with an antisense drug called ISIS 2922. This drug affects the way the CMV works, i.e., it may be able to destroy the virus without harming the patient. One study uses ISIS 2922 alone and the other combines it with ganciclovir. Participants must have CMV retinitis in one or both eyes and the condition must have progressed at least once while being treated with ganciclovir or foscarnet. ISIS 2922 will be injected directly into the eye globe; ganciclovir will be given intravenously. Participants must not be intolerant to ganciclovir, the infection must be peripheral, and there must be no opportunistic infection outside of the eye. More information can be obtained by calling The Network at (800) 734-7104.

Keywords: Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Cytomegalovirus Retinitis/*DRUG THERAPY Drug Administration Routes Drug Therapy, Combination Eye Ganciclovir/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Human Infusions, Intravenous NEWSLETTER ARTICLE RANDOMIZED CONTROLLED TRIAL CLINICAL TRIAL
950930
M9591262

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .